Hyundai Bioscience Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hyundai Bioscience Co., Ltd.
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
- Site Specific
- Drug Delivery
- Other Names / Subsidiaries
- CNPharm, Inc., Hyundai Bioscience Inc., Hyundai IBT Co. Hyundai IT Co.